Insulin Suppresses the Expression of Amyloid Precursor Protein ...

ORIGINAL E n d o c r i n e

ARTICLE R e s e a r c h

Insulin Suppresses the Expression of Amyloid Precursor Protein, Presenilins, and Glycogen Synthase Kinase-3␤ in Peripheral Blood Mononuclear Cells Paresh Dandona, Islam Mohamed, Husam Ghanim, Chang Ling Sia, Sandeep Dhindsa, Sonny Dandona, Antoine Makdissi, and Ajay Chaudhuri Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo and Kaleida Health, Buffalo, New York 14209

Objective: Our objective was to determine whether peripheral blood mononuclear cells express amyloid precursor protein (APP) and other mediators involved in the pathogenesis of Alzheimer’s disease and whether their expression is suppressed by insulin. Research Design and Methods: Ten obese type 2 diabetic patients were infused with insulin (2 U/h with 100 ml 5% dextrose/h) for 4 h. Patients were also infused with 5% dextrose/h or normal physiological saline for 4 h, respectively, on two other days as controls. Blood samples were obtained at 0, 2, 4, and 6 h. Results: Insulin infusion significantly suppressed the expression of APP, presenilin-1, presenilin-2, and glycogen synthase kinase-3␤ in peripheral blood mononuclear cells. Dextrose and saline infusions did not alter these indices. Insulin infusion also caused significant parallel reductions in nuclear factor-␬B binding activity and plasma concentrations of serum amyloid A and intercellular adhesion molecule-1. Conclusions: A low dose infusion of insulin suppresses APP, presenilin-1, presenilin-2, and glycogen synthase kinase-3␤, key proteins involved in the pathogenesis of Alzheimer’s disease, in parallel with exerting its other antiinflammatory effects. (J Clin Endocrinol Metab 96: 1783–1788, 2011)

D

erived from amyloid precursor protein (APP), ␤-amyloid (A␤) is the main component of the plaques that in the brain are the hallmark of Alzheimer’s disease (AD) (1). The other key pathological feature of AD is the neurofibrillary tangle formed by the ␶-protein, which needs to be hyperphosphorylated to form these tangles (2). This phosphorylation is mediated by the enzyme glycogen synthase kinase-3␤ (GSK-3␤) (3). Because these processes are related to inflammatory and oxidative stress-related changes in the brain, it is likely that conditions associated with increased oxidative stress and inflammation are associated with an increased incidence of AD. Indeed, obesity and type 2 diabetes mellitus (T2DM), known to be associated with chronic low-grade inflammation and ox-

idative stress, have a significantly increased prevalence of AD (4). Both states are also associated with insulin resistance. Several other factors are also involved in the deposition of the amyloid plaques. They include the enzymes ␤- and ␥-secretase, which convert APP into A␤, and the enzyme neprilysin, which breaks down A␤ (2, 5– 8). Presenilin-1 (PS1) and PS2 are two subunits of ␥-secretase. Thus, the assessment of any novel agent aimed at treating or preventing AD would necessitate the investigation of the effects of the agent on these mediators. Recent work has shown that insulin reduces the expression of A␤ in neuronal cultures in vitro and that A␤ reduces the expression of the insulin receptor in neurites in

ISSN Print 0021-972X ISSN Online 1945-7197 Printed in U.S.A. Copyright © 2011 by The Endocrine Society doi: 10.1210/jc.2010-2961 Received December 17, 2010. Accepted February 23, 2011. First Published Online March 16, 2011

Abbreviations: A␤, ␤-Amyloid; AD, Alzheimer’s disease; APP, amyloid precursor protein; BMI, body mass index; GSK-3␤, glycogen synthase kinase-3␤; HbA1c, glycosylated hemoglobin; MNC, mononuclear cell; NF␬B, nuclear factor-␬B; NS, not significant; PS1, presenilin-1; RMANOVA, repeated-measures ANOVA; sICAM, soluble intercellular adhesion molecule; T2DM, type 2 diabetes mellitus.

J Clin Endocrinol Metab, June 2011, 96(6):1783–1788

jcem.endojournals.org

1783

1784

Dandona et al.

Insulin Suppresses Amyloid Precursor Protein

these cultures (9). A␤ also induces oxidative stress in neurons, which is inhibited by insulin (9), consistent with the previously described reactive oxygen species’ suppressive effect on peripheral blood mononuclear cells (MNC) (10). Interestingly, it has also been shown that A␤ induces an increase in nuclear factor-␬B (NF␬B) binding activity and triggers inflammation (11). A recent study also demonstrated that intranasal inhalation of insulin improves cognitive function in patients with AD (12). Because intranasal administration leads to direct access of insulin into the brain along the olfactory nerves, insulin is able to exert a selective cerebral or neuronal action without its systemic effects on glycemic levels. Furthermore, there are data demonstrating that the expression of insulin, IGF-I and IGF-II receptors, insulin receptor substrate-1, phosphatidylinositol 3-kinase, and AkT kinase is diminished, whereas that of GSK-3␤ is increased in the brains of patients with AD (13). This study also showed that the expression of insulin, IGF-I, and IGF-II is diminished in these brains. Indeed, on this basis, the authors wondered whether AD could be termed type 3 diabetes. To explain the increase of AD in insulin-resistant proinflammatory states and the beneficial effects of insulin in AD patients in preliminary studies, it is important that its effects on these factors be investigated. Because our previous work has shown that iv-infused insulin exerts a potent and rapid antiinflammatory effect as manifested by its effect on peripheral blood MNC (10, 14 –16), we hypothesized that the MNC expresses APP and ␶-protein and that insulin suppresses their expression. In addition, we also hypothesized that insulin suppresses the expression of the ␥-secretase subunits PS1 and PS2 and GSK-3␤.

Subjects and Methods Subjects Twenty-four obese patients with T2DM participated in this study. They were on stable oral antidiabetic medications. All patients were on metformin (1–2 g/d), and 14 patients were on sulfonylureas (glyburide or glipizide 5–10 mg/d). None of the subjects was on insulin or thiazolidinedione therapy or taking any antioxidant or nonsteroidal antiinflammatory drugs. Subjects were divided into three groups of similar baseline characteristics and medications. Over 80% of patients were on stable doses of statins, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and aspirin. After an overnight fast, 10 subjects [five females, age 48 ⫾ 9 yr, with body mass index (BMI) of 39.2 ⫾ 6.5 kg/m2 and glycosylated hemoglobin (HbA1c) of 7.0 ⫾ 0.8%] were infused with insulin (2 U/h) with 5% glucose and 20 mEq potassium chloride for 4 h followed by 2 h of observation and washout. Blood glucose level was maintained within a target range of 80 –130 mg/dl for the entire group within 15 mg/dl from the baseline for each patient. Blood glucose was measured every 15 min. Another eight (four females, age


46 ⫾ 8 yr, with BMI of 38.6 ⫾ 7.2 kg/m2 and HbA1c of 7.3 ⫾ 0.9%) and six (four females, age 42 ⫾ 8 yr, with BMI of 37 ⫾ 6.7 kg/m2 and HbA1c of 7.5 ⫾ 1.1%) subjects were infused with either 5% glucose or normal saline alone, respectively, at a rate of 100 ml/h for 4 h and served as controls. Blood samples were collected at baseline and at 2, 4, and 6 h after the start of the infusion. The protocol was approved by the Human Research Committee of the State University of New York at Buffalo. An informed consent was signed by all subjects.

MNC isolation Blood samples were collected in Na-EDTA and carefully layered on Lympholyte medium (Cedarlane Laboratories, Hornby, Ontario, Canada). Samples were centrifuged and two bands separated out at the top of the red blood cell pellet. The MNC band was harvested and washed twice with Hanks’ balanced salt solution. This method provides yields greater than 95% MNC preparation.

Quantification of APP, PS1, PS2, ␶, and GSK-3␤ expression The mRNA expression of APP, PS1, PS2, GSK-3␤, and ␶ was measured in MNC by RT-PCR. Total RNA was isolated using commercially available RNAqueous-4PCR Kit (Ambion, Austin, TX). Real-time RT-PCR was performed using Stratagene (La Jolla, CA) Mx3000P QPCR System, Sybr green master mix (QIAGEN, Valencia, CA), and gene-specific primers (Life Technologies, Rockville, MD). All values were normalized to the expression of a group of housekeeping genes including actin, ubiquitin C, and cyclophilin A.

Western blotting MNC total cell lysates were prepared and electrophoresis and immunoblotting were carried out as described before (10). Monoclonal antibody against APP (Abcam, Cambridge, MA) and actin (Santa Cruz Biotechnology, Santa Cruz, CA) were used, and all values were corrected for loading to actin.

Plasma measurements Glucose concentrations were measured in plasma by YSI (Yellow Springs, OH) 2300 STAT Plus glucose analyzer. ELISA was used to measure plasma concentrations of insulin (Diagnostic Systems Laboratories Inc., Webster, TX), soluble intercellular adhesion molecule (sICAM) (R&D Systems, Minneapolis, MN), and SAA (Invitrogen, Carlsbad, CA) with coefficients of variation of 3–5 and 4.5–7%, respectively.

Statistical analysis Statistical analysis was conducted using SigmaStat software (SPSS Inc., Chicago, IL). All data are represented as mean ⫾ SE. Changes from baseline were calculated and statistical analysis was carried out using one-way repeated-measures ANOVA (RMANOVA) with Holm-Sidak post hoc test. Two-factor RMANOVA followed by Dunnett’s post hoc test was used for multiple comparisons between different treatments.

Results Insulin and glucose concentrations after insulin infusion Plasma insulin concentration increased from 20.9 ⫾ 10.9 to 50.5 ⫾ 22.4 ␮U/ml (P ⬍ 0.001) during the insulin



1785

significant change in the expression of these indices after the infusion of glucose or saline alone. The expression of PS1, PS2, and GSK-3␤ was too low to be detected by Western blots. Effect of insulin infusion on other inflammatory mediators Insulin infusion significantly suppressed the DNA binding of NF␬B by 14 ⫾ 5% at 4 h, whereas glucose or saline infusion caused no significant change in NF␬B activity (Fig. 3, P ⬍ 0.05). After insulin infusion, there was a significant decrease in plasma concentrations of SAA from 9.6 ⫾ 1.6 to 8.2 ⫾ 1.3 ␮g/ml (by 15 ⫾ 3%) and sICAM from 265 ⫾ 21 to 241 ⫾ 19 ng/ml (by 11 ⫾ 2%) (Fig. 4, P ⬍ 0.05). There was no significant change in plasma levels of these inflammatory mediators after dextrose or saline infusions. FIG. 1. Change in the mRNA expression of APP-1 (A) PS2 (B), PS1 (C), and GSK-3␤ (D) in MNC after 2 U/h insulin/dextrose infusion (insulin), dextrose alone (dextrose), or saline alone (saline) in obese T2DM for 4 h. Data are presented as mean ⫾ SE. *, P ⬍ 0.05 by one-way RMANOVA (compared with baseline); #, P ⬍ 0.05 by two-way RMANOVA (compared with control groups).

infusion, whereas it fell slightly in the dextrose group from 27.6 ⫾ 5.6 to 22.9 ⫾ 6.5 ␮U/ml at 4 h [not significant (NS)] and in the normal saline group from 20.6 ⫾ 5.5 to 17.9 ⫾ 4.7 ␮U/ml at 4 h (NS). The mean blood glucose concentrations changed from 122 ⫾ 15 at baseline to 111 ⫾ 10 mg/dl at 4 h (NS) after insulin infusion, and 133 ⫾ 14 mg/dl at baseline to 125 ⫾ 12 mg/dl at 4 h (NS) after dextrose infusion. Blood glucose concentration did not change in the saline group. Blood glucose at baseline and at 4 h was not significantly different between the three groups. No patient experienced hypoglycemia. Effect of insulin infusion on the expression of AD mediators in MNC The mRNA expression of APP fell significantly by 19 ⫾ 5% at 4 h after insulin infusion (Fig. 1A, P ⬍ 0.05). Insulin infusion also suppressed the mRNA expression of PS2 (subunit of ␥-secretase) by 24 ⫾ 9% at 4 h (Fig. 1B, P ⬍ 0.05). PS1 expression was suppressed at 6 h by 28 ⫾ 6% (Fig. 1C, P ⬍ 0.05), whereas there was no change in its expression at 4 h. There was no significant detectable expression of ␶ in MNC. However, the infusion of insulin significantly suppressed the expression of GSK-3␤ by 40 ⫾ 7% at 2 h (Fig. 1D, P ⬍ 0.05). There was also a concomitant fall in APP-1 protein levels in MNC by 17 ⫾ 7% at 4 h after insulin infusion (Fig. 2, P ⬍ 0.05). There was no

Discussion

Our data show for the first time that MNC express APP, PS1, PS2, and GSK3␤, which are some of the key proteins involved in the pathogenesis of AD. APP is the precursor of A␤, whereas PS1 and PS2 are components of ␥-secretase, the enzyme that cleaves APP at the cytoplasmic end. We did not observe a significant expression of ␶ in MNC. On the other hand, GSK-3␤, the enzyme responsible for hyperphosphorylating ␶ was expressed by the MNC. Thus, MNC can be used for investigating the effect of potential drugs that may affect the key proteins related to AD. Although APP expression has previously been shown in monocytic THP-1 cell lines in vitro (17), it has never been shown in peripheral blood MNC. Our data also demonstrate for the first time that the low-dose insulin infusion suppressed the mRNA expression of APP, PS1, PS2, and GSK-3␤. Although APP was suppressed significantly at 4 h, PS2 and GSK-3␤ were suppressed significantly at 2 h and continued to be suppressed thereafter. On the other hand, the suppression of PS1 was observed only at 6 h, 2 h after the cessation of the insulin infusion. Clearly, PS1 takes longer to suppress, and therefore, future studies would need to be conducted for prolonged periods of time. The known suppression of C-reactive protein by insulin also takes longer periods of infusion (18, 19). The expression of APP was also sup-

1786

Dandona et al.


FIG. 2. Representative Western blot (A) and percent change (B) in APP-1 protein levels by Western blotting from total cell lysates from MNC after 2 U/h insulin/dextrose infusion (insulin), dextrose alone (dextrose), or saline alone (saline) in obese T2DM for 4 h. Data are presented as mean ⫾ SE. *, P ⬍ 0.05 by one-way RMANOVA (compared with baseline); #, P ⬍ 0.05 by two-way RMANOVA (compared with control groups).

pressed significantly at 4 h. This effect appeared to linger at 6 h but was not significant at that time. Insulin has previously been known to reduce the enzymatic activity of GSK-3␤. However, our observation that its expression is reduced significantly in the human in vivo is novel. This observation is also relevant to the fact that the expression of GSK-3␤ is increased in the brains of patients with AD (13). Because there was no significant expression of ␶-protein in MNC, we shall have to investigate an effect of insulin on ␶ expression in some other tissue in which it is expressed. It is noteworthy that insulin can potentially inhibit the formation of A␤ in two ways, through the suppression of APP expression and the suppression of the two components of ␥-secretase, PS1 and PS2. In addition, insulin would inhibit the hyperphosphorylation of ␶ by suppressing the expression of GSK-3␤. The suppression of APP after the infusion of insulin occurred in parallel with the suppression of other indices of inflammation as reflected in decreased intranuclear NF␬B binding and decreased plasma concentrations of ICAM-1 and SAA. These effects were consistent with the


FIG. 3. Change in NF␬B DNA binding activity by EMSA to a consensus NF␬B binding site in nuclear extracts from MNC after 2 U/h insulin/ dextrose infusion (insulin), dextrose alone (dextrose), or saline alone (saline) in obese T2DM for 4 h. Data are presented as mean ⫾ SE. *, P ⬍ 0.05 by one-way RMANOVA (compared with baseline); #, P ⬍ 0.05 by two-way RMANOVA (compared with control groups).

previously demonstrated antiinflammatory effects of insulin including the suppression of chemokines, toll-like receptors, and reactive oxygen species generation (10, 15, 16). Because the pharmacodynamics of these effects on APP and other inflammatory indices were similar, and the other antiinflammatory effects did not precede APP suppression, it is likely that insulin has a direct cellular effect on APP, PS2, PS1, and GSK-3␤ expression in parallel with its other antiinflammatory actions. If indeed this effect of insulin is a systemic one and occurs in the brain, insulin could be a potential therapeutic agent in the treatment of AD. However, future larger studies are needed to confirm our data and also to confirm the potential benefits to cognitive function demonstrated by the pilot study by Craft’s group (12) using intranasal insulin. It is noteworthy the magnitude of NF␬B suppression in these patients was less than that described by us previously in obese patients. It is possible that obese patients with type 2 diabetes have a greater level of inflammation and insulin resistance. Consistent with the above effects, insulin has recently been shown to suppress the expression of A␤ by neurites in culture, whereas A␤ reduces the expression of insulin


FIG. 4. Change in plasma concentrations of SAA (A) and sICAM-1 (B) after 2 U/h insulin/dextrose infusion (insulin), dextrose alone (dextrose), or saline alone (saline) in obese T2DM for 4 h. Data are presented as mean ⫾ SE. *, P ⬍ 0.05 by one-way RMANOVA (compared with baseline); #, P ⬍ 0.05 by two-way RMANOVA (compared with control groups).

receptor in neurites (9). A recent report shows that metformin induces an increase in the expression of APP in vitro. However, the incubation of metformin with insulin showed a synergistic effect of metformin with the suppressive effect of insulin (20). This interesting relationship between the key pathogenic peptide of AD and insulin is clearly of interest and points to a potential therapeutic role for insulin in the treatment of this disease. It is also conceptually consistent with insulin resistance being a predisposing factor for AD. In a recent study, intranasal administration of insulin was shown to improve cognitive function in patients with AD (12). In contrast to insulin, glucose is known to induce oxidative stress and inflammation (21). Hyperglycemia in diabetics has recently been shown to be associated with impaired cognitive ability when compared with those with normal glycemic levels (22). Recent work has revealed another interesting relationship between A␤ and diabetes. Crossbreeding of an APP transgenic mouse and the ob/ob mouse leads to a pheno-


1787

type with extremely severe insulin resistance and T2DM (23). It is, therefore, possible that A␤ may play other important pathogenic roles including an increase in insulin resistance and diabetogenicity. Thus, our observations on the suppression of APP, PS1, PS2, and GSK-3␤ by insulin may have implications beyond those for AD. Furthermore, it has been shown that A␤ is capable of inducing increased NF␬B binding and to induce molecular changes of inflammation (11, 24). This observation suggests that the role of A␤ in inflammatory processes may potentially be systemic, beyond its currently recognized cerebral actions. By implication, therefore, the suppressive effect of insulin on NF␬B binding would systemically be inhibitory of the potential proinflammatory effect of A␤. Recent work has demonstrated that APP acts as a proinflammatory mediator in endothelial cells, THP-1 monocytic cell lines, and microglia. Its distribution in the cell membrane is close to ␤-integrins, and thus, its activation by elements of extracellular matrix induces cytokine generation (25) and increases the adhesion characteristics of these cells (26). It is also expressed in vascular tissue. On the basis of the above evidence, APP may exert its proinflammatory effects in various organs including the brain, independently of its product, A␤ (27). Thus, the suppression of APP by insulin may exert a further systemic antiinflammatory effect. The obvious weakness of this paper is the absence of data from neurons. However, because that is not possible in humans in vivo, a surrogate cellular model is important. Our data provide that. Further exploration using adipose tissue may be another alternative because that tissue expresses a range of AD-related proteins. Another shortcoming of our data is the lack of protein expression for PS1, PS2, and GSK-3␤ due to our inability to obtain Western blots. Future studies will have to investigate this aspect with more refined techniques. In conclusion, APP and ␥-secretase complex proteins PS1 and PS2 are expressed in the MNC; a low-dose insulin infusion promptly reduces the expression of APP, PS1, and PS2, in parallel with the reduction in NF␬B binding and the expression of several proinflammatory mediators. Insulin also suppresses GSK-3␤ expression, the enzyme responsible for the hyperphosphorylation of ␶. Clearly, insulin has the potential of being developed as a therapeutic agent for AD for which no satisfactory treatment is currently available.

Acknowledgments Address all correspondence and requests for reprints to: Paresh Dandona, B.Sc., M.D., D.Phil. (Oxon), F.R.C.P., Director, Diabetes-Endocrinology Center of Western New

1788

Dandona et al.


York, Chief of Endocrinology, State University of New York at Buffalo, 3 Gates Circle, Buffalo, New York 14209. E-mail: [email protected]. P.D. is supported by grants from the National Institutes of Health (R01 DK069805 and RO1 DK075877) and the American Diabetes Association (708CR13) and by grants from Merck, Amylin, and Abbott Pharmaceuticals. S.D. is supported by a grant from the American Diabetes Association. Participation and Contribution: P.D. was responsible for the hypothesis, planning, analysis of data, and writing; I.M. for laboratory analytical work; H.G. for planning, supervision and coordination of laboratory work, statistical analysis, and writing; C.L.S. for laboratory analysis; S.Dh. for planning, supervision of infusions, and writing; S.Da. for the original idea and hypothesis; A.M. for analysis of data and writing; and A.C. for planning, supervision of recruitment, and infusions. Disclosure Summary: I.M., H.G., C.L.S., S.Dh., S.Da., A.M., and A.C. have nothing to disclose.


13.

14.

15.

16.

17.

18.

References 1. Selkoe DJ 2001 Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766 2. Selkoe DJ 1999 Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 399:A23–A31 3. Hernańdez F, Go´mez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J 2010 GSK3: A possible link between beta amyloid peptide and tau protein. Exp Neurol 223:322–325 4. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA 2004 Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61:661– 666 5. Haass C, Selkoe DJ 1993 Cellular processing of ␤-amyloid precursor protein and the genesis of amyloid ␤-peptide. Cell 75:1039 –1042 6. Chow VW, Mattson MP, Wong PC, Gleichmann M 2010 An overview of APP processing enzymes and products. Neuromolecular Med 12:1–12 7. Thinakaran G, Koo EH 2008 Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615–29619 8. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S 2008 A␤-degrading enzymes in Alzheimer’s disease. Brain Pathol 18:240 – 252 9. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL 2009 Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of A␤ oligomers. Proc Natl Acad Sci USA 106:1971–1976 10. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S 2001 Insulin inhibits intranuclear nuclear factor ␬B and stimulates I␬B in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257– 3265 11. Combs CK, Karlo JC, Kao SC, Landreth GE 2001 ␤-Amyloid stimulation of microglia and monocytes results in TNF␣-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21:1179 –1188 12. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey 2nd WH,

19.

20.

21.

22.

23.

24.

25.

26.

27.

Craft S 2008 Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-␤ in memory-impaired older adults. J Alzheimers Dis 13:323–331 Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM 2005 Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer’s disease: is this type 3 diabetes? J Alzheimers Dis 7:63– 80 Dandona P, Aljada A, Mohanty P, Ghanim H, Bandyopadhyay A, Chaudhuri A 2003 Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 26:3310 –3314 Ghanim H, Mohanty P, Deopurkar R, Sia CL, Korzeniewski K, Abuaysheh S, Chaudhuri A, Dandona P 2008 Acute modulation of toll-like receptors by insulin. Diabetes Care 31:1827–1831 Ghanim H, Korzeniewski K, Sia CL, Abuaysheh S, Lohano T, Chaudhuri A, Dandona P 2010 Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care 33:1103– 1108 Sondag CM, Combs CK 2010 Adhesion of monocytes to type I collagen stimulates an APP-dependent proinflammatory signaling response and release of A␤1– 40. J Neuroinflammation 7:22 Chaudhuri A, Janicke D, Wilson MF, Tripathy D, Garg R, Bandyopadhyay A, Calieri J, Hoffmeyer D, Syed T, Ghanim H, Aljada A, Dandona P 2004 Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 109:849 – 854 Visser L, Zuurbier CJ, Hoek FJ, Opmeer BC, de Jonge E, de Mol BA, van Wezel HB 2005 Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normoglycaemic clamp: effects on inflammatory response during coronary artery surgery. Br J Anaesth 95:448 – 457 Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF 2009 Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 106:3907–3912 Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P 2000 Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85:2970 –2973 Saczynski JS, Jońsdo´ttir MK, Garcia ME, Jonsson PV, Peila R, Eiriksdottir G, Olafsdottir E, Harris TB, Gudnason V, Launer LJ 2008 Cognitive impairment: an increasingly important complication of type 2 diabetes. Am J Epidemiol 168:1132–1139 Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R 2010 Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and A␤ deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107:7036 –7041 Paris D, Patel N, Quadros A, Linan M, Bakshi P, Ait-Ghezala G, Mullan M 2007 Inhibition of A␤ production by NF-␬B inhibitors. Neurosci Lett 415:11–16 Sondag CM, Combs CK 2006 Amyloid precursor protein crosslinking stimulates ␤ amyloid production and pro-inflammatory cytokine release in monocytic lineage cells. J Neurochem 97:449 – 461 Susan AA, Colin KC 2010 Amyloid precursor protein mediates monocyte adhesion in AD tissue and apoE⫺/⫺ mice. Neurobiol Aging 31:1854 –1866 Simoń AM, Schiapparelli L, Salazar-Colocho P, Cuadrado-Tejedor M, Escribano L, Lo´pez de Maturana R, Del Río J, Pe´rez-Mediavilla A, Frechilla D 2009 Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to A␤ levels. Neurobiol Dis 33:369 –378